We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
-18.55%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$2.33B
AUM Growth
-$894M
Cap. Flow
-$130M
Cap. Flow %
-5.55%
Top 10 Hldgs %
69.04%
Holding
126
New
9
Increased
16
Reduced
12
Closed
23

Top Buys

Rank Stock Value
1
NMRA icon
Neumora Therapeutics
NMRA
+$35M
2
APLS
Apellis Pharmaceuticals
APLS
+$27M
3
SLRN
ACELYRIN
SLRN
+$13.8M
4
IMGN
Immunogen Inc
IMGN
+$12.4M
5
SGMT icon
Sagimet Biosciences
SGMT
+$12.3M

Top Sells

Rank Stock Value
1
KRYS icon
Krystal Biotech
KRYS
+$41.1M
2
SAGE
Sage Therapeutics
SAGE
+$23.5M
3
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$20.4M
4
RLAY icon
Relay Therapeutics
RLAY
+$15.2M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$13.8M

Sector Composition

Rank Sector Weight
1 Healthcare 54.42%
2 Consumer Discretionary 42.85%
3 Technology 0.61%
4 Communication Services 0.19%
5 Real Estate 0.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VTYX
26
DELISTED
Ventyx Biosciences
VTYX
$14.1M 0.6%
405,239
-3,280
-0.8% -$113K
ALPN
27
DELISTED
Alpine Immune Sciences Inc
ALPN
$13.7M 0.59%
1,193,030
– –
CBIO
28
Crescent Biopharma
CBIO
$546M
$12.9M 0.55%
85,891
– –
RYZB
29
DELISTED
RayzeBio, Inc. Common Stock
RYZB
$12.3M 0.53%
+555,556
New +$11.7M
GERN icon
30
Geron
GERN
$898M
$11.8M 0.51%
5,565,889
– –
ROIV icon
31
Roivant Sciences
ROIV
$23.6B
$11.7M 0.5%
1,000,000
-625,000
-38% -$7.07M
TSHA icon
32
Taysha Gene Therapies
TSHA
$1.61B
$11.6M 0.5%
3,663,104
+2,222,222
+154% +$4.15M
WVE icon
33
Wave Life Sciences
WVE
$1.12B
$11.5M 0.49%
2,000,000
-870,523
-30% -$3.97M
GBIO
34
DELISTED
Generation Bio
GBIO
$10.7M 0.46%
281,419
– –
SEER icon
35
Seer Inc
SEER
$114M
$10.5M 0.45%
4,750,000
– –
VIGL
36
DELISTED
Vigil Neuroscience
VIGL
$10.3M 0.44%
1,908,135
-3,056
-0.2% -$21.1K
RNAC icon
37
Cartesian Therapeutics
RNAC
$218M
$9.69M 0.42%
304,555
– –
OVID icon
38
Ovid Therapeutics
OVID
$427M
$9.6M 0.41%
2,500,000
– –
ERAS icon
39
Erasca
ERAS
$6.15B
$9.3M 0.4%
4,721,194
– –
TSM icon
40
TSMC
TSM
$1.94T
$8.93M 0.38%
102,699
+60,199
+142% +$5.69M
NTRA icon
41
Natera
NTRA
$36.4B
$8.85M 0.38%
200,000
– –
NBTX
42
Nanobiotix
NBTX
$1.92B
$8.75M 0.38%
1,000,000
– –
NTLA icon
43
Intellia Therapeutics
NTLA
$1.51B
$8.73M 0.37%
276,077
– –
FHTX icon
44
Foghorn Therapeutics
FHTX
$278M
$8.6M 0.37%
1,720,720
– –
REPL icon
45
Replimune Group
REPL
$454M
$8.55M 0.37%
500,000
– –
RPTX
46
DELISTED
Repare Therapeutics
RPTX
$8.46M 0.36%
700,000
– –
SGMT icon
47
Sagimet Biosciences
SGMT
$435M
$8.14M 0.35%
+924,771
New +$12.3M
IMA
48
ImageneBio Inc
IMA
$63.4M
$8.01M 0.34%
154,126
– –
AUPH icon
49
Aurinia Pharmaceuticals
AUPH
$1.95B
$7.77M 0.33%
1,000,000
– –
VRDN icon
50
Viridian Therapeutics
VRDN
$2.2B
$7.75M 0.33%
504,978
– –
1
2
3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q3 2023 Portfolio in Review

As of Q3 2023, Artal Group held 126 positions worth $2.33B, down 28% from $3.23B the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Artal Group withdrew a net $130M in Q3 2023, closing 23 positions and reducing 12 holdings. Its most notable exit was Krystal Biotech, an estimated $41.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 54% of assets, down from 55% a quarter earlier, followed by Consumer Discretionary and Technology.

Against the trend, Artal Group opened a new position in Neumora Therapeutics worth $39.5M.

  • Artal Group's largest Q3 2023 buy was Neumora Therapeutics: 2,802,702 shares worth $39.5M.
  • Artal Group added most to Apellis Pharmaceuticals in Q3 2023, an estimated $27M increase.
  • Artal Group's biggest Q3 2023 reduction was Schrodinger, cutting an estimated $8.06M.
  • Artal Group fully exited Krystal Biotech in Q3 2023, selling an estimated $41.1M.
  • Artal Group's ten largest holdings make up 69% of its $2.33B portfolio in Q3 2023.
  • Artal Group opened 9 new positions and closed 23 in Q3 2023.
  • Artal Group's portfolio value fell 28% quarter-over-quarter to $2.33B.

Based on Artal Group's 13F filing for Q3 2023, filed 13 Nov 2023.